Enanta Pharmaceuticals | Capitaux Propres Et Réserves





Capitaux Propres Et Réserves Changement Date
AbbVie USD -2.64B 2.46B 2025-09
Amgen USD 9.62B 2.19B 2025-09
Anika Therapeutics USD 146.8M 867K 2025-09
Arrowhead Research USD 568.42M 102.37M 2025-12
AstraZeneca USD 45.89B 1.17B 2025-09
BioCryst Pharmaceuticals USD -387.89M 33.7M 2025-09
Biogen USD 18.21B 573.5M 2025-09
Bristol-Myers Squibb USD 18.55B 1.06B 2025-09
Enanta Pharmaceuticals USD 64.72M 14.56M 2025-09
Gilead Sciences USD 21.46B 1.78B 2025-09
GlaxoSmithKline GBP 16.38B 229M 2025-12
Halozyme Therapeutics USD 503.92M 171.17M 2025-09
Heron Therapeutics USD 14.88M 42.14M 2025-09
Immunic USD 10.5M 23.41M 2025-09
Incyte USD 5.17B 516.28M 2025-12
Insmed USD 945.57M 304.16M 2025-09
Ionis Pharmaceuticals USD 617.97M 13.76M 2025-09
J&J USD 78.47B 0 2025-09
Karyopharm Therapeutics USD -269.26M 30.33M 2025-09
Ligand Pharmaceuticals USD 950.17M 121.64M 2025-09
Merck USD 51.85B 2.79B 2025-09
Neurocrine Biosciences USD 3B 309.3M 2025-09
Novartis USD 44.75B 2.7B 2025-09
Novavax USD -156.67M 194.3M 2025-09
Pfizer USD 92.8B 4.11B 2025-09
PTC Therapeutics USD -155.76M 50.79M 2025-09
Roche Holding CHF 33.8B 758M 2025-12
Sarepta Therapeutics USD 1.32B 37.26M 2025-09
Vertex Pharmaceuticals USD 17.32B 143.4M 2025-09


Enanta Pharmaceuticals Capitaux Propres Et Réserves - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Feb 2026.